Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 5/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | KLK7 | P49862 | 2/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599808 | 0.92 | TPSAB1 (0.44) | ALDH1A1 | |
| SCHEMBL2292771 | 0.92 | TPSAB1 (0.44) | ALDH1A1 | |
| SCHEMBL4600306 | 0.92 | TPSAB1 (0.44) | ALDH1A1 | |
| SCHEMBL4600478 | 0.91 | TPSAB1 (0.43) | — | |
| SCHEMBL4600039 | 0.90 | KMT2A (0.47) | JAK3BTK | |
| SCHEMBL4599868 | 0.90 | KMT2A (0.47) | JAK3BTK | |
| SCHEMBL1637220 | 0.90 | KMT2A (0.47) | JAK3BTK | |
| SCHEMBL4612508 | 0.86 | MALT1 (0.43) | CTSSCTSK | |
| SCHEMBL4717209 | 0.86 | MALT1 (0.43) | CTSSCTSK | |
| SCHEMBL4600319 | 0.80 | SYK (0.40) | CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796756-B2 | Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-3192800-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | Arrowhead Pharmaceuticals, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-2652134-B1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | ARROWHEAD PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20160102120-A1 | Galactose Cluster-Pharmacokinetic Modulator Targeting Moiety for siRNA | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2016-04-14 | — | — | US | disclosed |
| US-9249179-B2 | Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA | Arrowhead Madison Inc. (US) | 2016-02-02 | — | — | US | disclosed |
| EP-2652134-A2 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | Arrowhead Research Corporation (US) | 2013-10-23 | — | — | EP | disclosed |
| WO-2012083046-A2 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR SIRNA | ARROWHEAD RESEARCH CORPORATION (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | ARROWHEAD RESEARCH CORPORATION | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102120-A1 | Galactose Cluster-Pharmacokinetic Modulator Targeting Moiety for siRNA | GALK1, GALE, GALNT6 | CXCR3 2355/4885CA1 4772/4885CA2 4836/4885 |
| US-20120157509-A1 | GALACTOSE CLUSTER-PHARMACOKINETIC MODULATOR TARGETING MOIETY FOR siRNA | GALK1, GALE, GALNT6 | CXCR3 2355/4885CA1 4772/4885CA2 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.